Medtronic, Inc.

30-day safety data available for coronary stent

Published in MD Week, June 25th, 2004

Minneapolis-based Medtronic announced 30-day safety data on the Endeavor II trial, which is a randomized, double-blind trial evaluating the safety and efficacy of the Endeavor Drug Eluting Coronary Stent compared to Medtronic's Driver cobalt alloy stent.

Safety data were presented by Richard Kuntz, M.D., associate professor at Harvard Medical Shool, at the Paris Course on Revascularization.

The Endeavor II trial includes 1,200 patients enrolled at more than 70 hospitals throughout Europe, the Middle East and Asia Pacific. The primary endpoint of the study is target vessel failure (TVF) at nine months. The other co-Principal investigators on the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of MD Week

Source: MD Week (2004-06-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry